AP13 Rec'd PCT/PTO 20 DEC 2506

FORM PTO-1390 (Modified) REV. 7-2005) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE TRANSMITTAL LETTER TO THE UNITED STATES 007123.00001 DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/594,443 CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/JP2005/006820 31 March 2005 31 March 2004 TITLE OF INVENTION COMPOSITION HAVING ANTITUMOR EFFECT APPLICANT(S) FOR DO/EO/US KOTANI, Hitoshi et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. \boxtimes This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below. The US has been elected (Article 31). 4 5. \Box A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). b. 🗀 has been communicated by the International Bureau. c. 🗆 is not required, as the application was filed in the United States Receiving Office (RO/US). П An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗍 is attached hereto. b. □ has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. 🗀 have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). A copy of the International Preliminary Examination Report (PCT/IPEA/409). 11. 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13 \boxtimes An Information Disclosure Statement under 37 CFR 1.97 and 1.98. \boxtimes 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. П A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. 17 A substitute specification. 18. A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 21. 22 Express Mail Label No.

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

.U.S. APPLICATION NO (if known, see 37 CFR 1.5)		CFR 1.5) INTERNATIONAL	INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMB		
10/594,443		PCT/JP20	005/006820	007123	007123.00001		
23. Other ite	ms or information:						
The followin	g fees have been sub	mitted:		CALCULATIONS	PTO US		
24. Basic n	00 \$ \$0.	00					
25. Examin If the written opin prepared by IPEA All other situation	ort \$ \$0.0	00					
If the written opin by IPEA/US Search fee (37 C as an Inter International Sea previously	fee (37 CFR 1.492(b) iionof the ISA/US or th	\$ \$0.0	00				
TOTA	L OF 24, 25 and 26	\$ \$0.0	00				
	e for specification and ting in compliance wit electronic medium) (3 250 for each additiona						
Total Sheets	Extra Sheets fr	Number of each additional 50 action thereof (round up to a w					
- 100 =	0 /50 =	0	× \$250.00	\$ \$0.0	00		
Surcharge of \$13 declaration after	0.00 for furnishing an	of the search fee, examination ment of the national stage (37	n fee, or the oath or CFR 1.492(h)).	\$ \$130.	00		
CLAIMS	NUMBER FILE	D NUMBER EXTRA	RATE				
Total claims	-	20 = 0	× \$50.00	\$ \$0.0	00		
Independent clair	ms -	3 = 0	× \$200.00	\$ \$0.0	00		
MULTIPLE DEP	ENDENT CLAIMS (if a	pplicable)	+ \$360.00	\$ \$0.0	00		
		= \$ \$130.0					
☐ Applicant cla	Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by						
	\$ \$0.6 = \$ \$130.6						
Processing fee of the earliest claim	\$ \$0.0						
	= \$ \$130.0	00					
Fee for recording accompanied by	an appropriate cover	TOTAL FEES ENCLOSED =					
Fee for recording accompanied by	an appropriate cover			= \$ \$170.0	00		
Fee for recording accompanied by	an appropriate cover			= \$ \$170.0 Amount to be	\$		

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007, OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a.		A check in the amount of \$	to cover the	e above fees is enclose	d.		
b.	X	Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed.	19-0733	in the amount of \$	\$170.00	to cover the above fees.	
C.		The Commissioner is hereby authorized to cl to Deposit Account No.		tional fees which may to copy of this sheet is end		credit any overpayment	
d.		Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
SE	ND A	ALL CORRESPONDENCE TO:		Frak	Lleuwen	dira	
Banner & Witcoff Ltd.				SIGNATUR	RE	J	
Deposit Acct. No. 19-0733			Lisa M. H	Lisa M. Hemmendinger			
				NAME			
				42,653			
				REGISTRA	TION NUMBE	R	
				Decembe	r 20, 2006		
				DATE			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
KOTANI, Hitoshi et al.) Attorney Docket No. 007123.00001
Serial No. 10/594,443) Group Art Unit: TBA
Filed: September 26, 2006) Examiner: Not Yet Assigned
For: COMPOSITION HAVNG ANTITUMOR EFF.	ECT
SUBMISSION OF DECLA	ARATION DOCUMENT
U.S. Patent and Trademark Office Randolph Building 401 Dulany Street Alexandria, VA 22314	
Sir:	
Submitted herewith is a copy of the i	nventors' executed Declaration for the national
phase application referenced above.	
Please note: To date, we have not receive	ved a Notification of Missing Requirements. The
attached Transmittal Letter includes the surcharge	e for filing the declaration after the thirty month
period.	
	Respectfully submitted,
Dated: December 20, 2006	By: Lisa M. Hemmendinger

Registration No.: 42,653

Banner & Witcoff, Ltd. Customer No.: 22907

LMH:rms